Iovance Biotherapeutics, Inc. (IOVA) stock soared 5.31% in the pre-market session on Monday, following positive analyst coverage from Chardan Capital and Truist Financial.
Chardan Capital reiterated its "Buy" rating on the biopharmaceutical company, while Truist Financial also maintained a "Buy" rating on IOVA shares. The analysts' positive outlook on the company's prospects appears to have fueled investor confidence, driving the stock's significant pre-market gain.
Despite the lack of specific details regarding the analysts' rationale for their bullish stance, the market seems to have responded favorably to the reaffirmation of "Buy" ratings from these respected firms, suggesting optimism about Iovance Biotherapeutics' future growth and performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。